SKP2 Recombinant Monoclonal Antibody

說明書

中文名稱：

SKP2重組抗體
貨號：

CSB-RA155372A0HU
規(guī)格：

￥1320
圖片：
Immunofluorescence staining of HepG2 Cells with CSB-RA155372A0HU at 1:50, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeated by 0.2% TritonX-100, and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4℃. Nuclear DNA was labeled in blue with DAPI. The secondary antibody was FITC-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L).

Overlay histogram showing Hela cells stained with CSB-RA155372A0HU (red line) at 1:50. The cells were fixed with 70% Ethylalcohol (18h) and then incubated in 10% normal goat serum to block non-specific protein-protein interactions followedby the antibody (1μg/1*10⁶ cells) for 1 h at 4℃.The secondary antibody used was FITC-conjugated goat anti-rabbit IgG (H+L) at 1/200 dilution for 30min at 4℃. Control antibody (green line) was Rabbit IgG (1μg/1*10⁶ cells) used under the same conditions. Acquisition of >10,000 events was performed.
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品描述：

CSB-RA155372A0HU SKP2重組單克隆抗體是針對人源S期激酶相關蛋白2（SKP2）開發(fā)的高特異性科研試劑。該抗體靶向的SKP2蛋白是SCF-SKP1-CUL1-F-box泛素連接酶復合物的核心組分，通過介導細胞周期調控蛋白（如p27等）的泛素化降解參與細胞增殖、腫瘤發(fā)生及DNA損傷應答等關鍵生物學過程。經多平臺驗證，本產品在酶聯(lián)免疫吸附實驗（ELISA）中展現(xiàn)優(yōu)異抗原結合能力，同時在免疫熒光（IF）和流式細胞術（FC）應用中呈現(xiàn)清晰的亞細胞定位信號與穩(wěn)定的細胞群體標記效果，推薦工作濃度分別為IF 1:20-1:200和FC 1:20-1:200。其高批次間一致性可滿足細胞周期動力學研究、腫瘤模型構建及蛋白質相互作用分析等科研需求，特別適用于探究癌癥發(fā)生機制、細胞增殖調控網絡及相關信號通路的研究場景，為體外實驗提供可靠的分子檢測工具。
Uniprot No.：

Q13309
基因名：

SKP2
別名：

S-phase kinase-associated protein 2 (Cyclin-A/CDK2-associated protein p45) (F-box protein Skp2) (F-box/LRR-repeat protein 1) (p45skp2), SKP2, FBXL1
反應種屬：

Human
免疫原：

A synthesized peptide derived from human SKP2
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
克隆類型：

Monoclonal
抗體亞型：

Rabbit IgG
純化方式：

Affinity-chromatography
克隆號：

3C11
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.
產品提供形式：

Liquid
應用范圍：

ELISA, IF, FC

推薦稀釋比：

Application	Recommended Dilution
IF	1:20-1:200
FC	1:20-1:200

Protocols：

ELISA Protocol
Immunofluorescence (IF) Protocol
Flow cytometry (FC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins involved in cell cycle progression, signal transduction and transcription. Specifically recognizes phosphorylated CDKN1B/p27kip and is involved in regulation of G1/S transition. Degradation of CDKN1B/p27kip also requires CKS1. Recognizes target proteins ORC1, CDT1, RBL2, KMT2A/MLL1, CDK9, RAG2, FOXO1, UBP43, YTHDF2, and probably MYC, TOB1 and TAL1. Degradation of TAL1 also requires STUB1. Recognizes CDKN1A in association with CCNE1 or CCNE2 and CDK2. Promotes ubiquitination and destruction of CDH1 in a CK1-dependent manner, thereby regulating cell migration.; Through the ubiquitin-mediated proteasomal degradation of hepatitis C virus non-structural protein 5A, has an antiviral activity towards that virus.
基因功能參考文獻：
1. MiR-339 targets the 3'-untranslated region of Skp2 mRNA to depress the proliferation of lung cancer cells. PMID: 29377618
2. Report that YAP is subject to non-proteolytic, K63-linked polyubiquitination by the SCF(SKP2) E3 ligase complex (SKP2), which is reversed by the deubiquitinase OTUD1. The non-proteolytic ubiquitination of YAP enhances its interaction with its nuclear binding partner TEAD, thereby inducing YAP's nuclear localization, transcriptional activity, and growth-promoting function. PMID: 29891922
3. BTrCP-FBXW2-SKP2 axis forms an oncogene-tumour suppressor-oncogene cascade to control cancer cell growth with FBXW2 acting as a tumour suppressor by promoting SKP2 degradation. PMID: 28090088
4. Result demonstrated that the overexpression of S-phase kinase-associated protein 2 (Skp2) was closely involved in the resistance of osteosarcoma cells to methotrexate and in the acquirement of EMT properties. PMID: 29620168
5. The role of USP18 in breast cancer provides a novel insight into the clinical application of the USP18/AKT/Skp2 pathway. PMID: 29749454
6. SKP2 promotes HCC progression and its nuclear functions of autophagy induction with CARM1 and AMPK, which may provide a potential target for HCC therapy. PMID: 29991055
7. The results of the present study revealed that miR340 serves a tumor suppressor role by influencing the proliferation, apoptosis, migration and invasion of HCC cell lines, which may be explained by the downregulation of SKP2 by miR340. PMID: 28944918
8. Our findings revealed that targeting Skp2 could be a promising therapeutic strategy for the treatment of Osteosarcoma PMID: 28627672
9. Levels of p21 and p27 were decreased in TACO or pAKT overexpressing HCC due to SKP2 upregulation. PMID: 27779207
10. Skp2 exhibited an oncogenic function in osteosarcoma cells. PMID: 28771075
11. The results suggest that Skp2 repression is important for sustaining tetraploid G1 arrest after cytokinesis blockade and is required to prevent uncoupled DNA replication and nuclear division without cytokinesis. PMID: 28648144
12. DCUN1D3 has a role in activating SCFSKP2 ubiquitin E3 ligase activity through cullin-1 neddylation and cell cycle progression in tumor cells with UV damage PMID: 27542266
13. The expression of p-Skp2 was associated with p-mTOR in GC cell lines and tissues. Interestingly, the combination of p-Skp2 and p-mTOR was a better predictor of survival than either factor alone PMID: 28446188
14. Atorvastatin strengthens Skp2 binding to FOXO1 or ICAM1, leading to ubiquitination and degradation. Skp2-dependent ubiquitination of major pathogenic molecules is the key mechanism for statin's protective effect on endothelial function in diabetes. PMID: 28802579
15. we identified that rottlerin exhibited its anti-tumor potential partly through inactivation of Skp2 in breast cancer PMID: 27582552
16. These findings indicated that SKP2 inhibition sensitized the prolactinoma cells to bromocriptine and helped promote apoptosis. PMID: 27488872
17. Skp2 suppressed p53 and inhibited PIG3-induced apoptosis, while Skp2B attenuated the function of PIG3 by inhibiting PHB. PMID: 27111245
18. Data suggest that targeting S-phase kinase associated protein 2 (SKP2) may serve as a potential radiosensitizer for developing effective therapeutic strategies against cervical cancer. PMID: 27317767
19. Data indicate a positive correlation of Skp2 and MTH1 expression in melanoma cell lines and patient specimens. PMID: 28947420
20. These results indicated that at least some oncogenic functions of BAG3 were mediated through posttranscriptional regulation of Skp2 via antagonizing suppressive action of miR-21-5p in ovarian cancer cells. PMID: 28624440
21. High SKP2 expression is associated with Non-Small Cell Lung Cancer. PMID: 28872922
22. Skp2-mediated degradation of Cygb was identified as the key mechanism for controlling its oscillating levels during the cell cycle. PMID: 28948618
23. FOXM1 may play a central role in the skp2-cdk1 loop driving tumor progression. PMID: 27684411
24. simvastatin also increased p21 and p27 expression in tumor sections by reducing Skp2 expression and inducing AMPK activation and STAT3 suppression in the same tumor tissues. PMID: 28230855
25. Structural mimicry by a bacterial AnkB to human Skp2 hijacks the host ubiquitin-proteasome system. PMID: 28111017
26. p27 and its cognate ubiquitin ligases, Skp2/KPC/Pirh2, are specifically involved in determining the clinical profiles of lung carcinomas. PMID: 28601655
27. direct interactions of MAGE-A11 with Skp2 and cyclin A regulate the substrate-specificity of Skp2-mediated protein degradation. PMID: 27720894
28. abnormal levels of Skp2 and p27(KIP1) have probably been involved in the pathogenesis of ADH and DCIS. Thus, Skp2 and p27(KIP1) may serve as important diagnosis markers PMID: 28514182
29. High SKP2 expression is associated with lung cancer. PMID: 28789966
30. our results revealed a novel mechanism in which EZH2 stability is regulated by SKP2 through the TRAF6-mediated and K63-linked ubiquitination, which contributes to elevated levels of H3K27me3 during prostate tumorigenesis and CRPC growth. PMID: 27869166
31. Data demonstrate that AMPKa2 protein levels are reduced in bladder cancer and that this reduction is correlated with an increase in SKP2 expression with a concomitant reduction in p27 protein levels. PMID: 27638620
32. SKP2 expression can inhibit radiation induced bystander effect of esophageal cancer cells. The mechanism may function, at least partly, through the regulation of Rad51 in the ability to repair DNA damage. PMID: 28178195
33. AMPK deficiency results in nuclear CARM1 decrease mediated in part by SKP2, contributing to autophagy dysfunction in the aged heart. PMID: 28315332
34. Higher expression of Skp2 correlates with lower expression of p27kip1 in gastric cancer tissues. PMID: 27572672
35. The suppression of Skp2 reduced the enzyme activities of MMP-2. PMID: 26874697
36. Data suggest that mternally expressed gene 3 (Meg3) long non-coding RNA and microRNA miR-3163 may coordinate suppression of translation of S-phase kinase associated protein 2 (Skp2) mRNA in non-small cell lung cancer (NSCLC) cells to inhibit cell growth. PMID: 26482610
37. Data suggest that SIRT2 may induce Skp2 deacetylation and subsequent degradation to abolish the effects of Skp2 on p27 to affect NSCLC cell growth. PMID: 26942878
38. High expression of SKP2 is associated with non-muscle invasive urothelial bladder carcinoma. PMID: 26932430
39. HDACIs effects on Skp2 protein posttranslational modifications and/or on its removal PMID: 26682002
40. miR-186 has a suppressive role in esophageal squamous cell carcinoma progression via SKP2-mediated pathway PMID: 26568291
41. Patients with breast cancer have an increased SKP2 level. Interference in SKP2 gene expression can inhibit breast cancer cell growth. PMID: 26345857
42. High expression of SKP2 is associated with Advanced Ovarian Cancer. PMID: 26320455
43. Results demonstrate that curcumin exerts its antitumor activity through inhibition of glioma cell Skp2 pathway. PMID: 26046466
44. TRUSS is a novel substrate of E3 ligase Skp2. PMID: 26038816
45. Overexpression of LKB1 and Skp2 is found in hepatocellular carcinoma patients and predicts poor survival outcomes. PMID: 25728766
46. The Skp2-mH2A1-CDK8 axis has a critical role in breast cancer development via dysregulation of the G2/M transition, polyploidy, cell growth dysregulation, and loss of tumor suppression. PMID: 25818643
47. the Skp2mediated degradation of p27kip1 was important in the proliferation of tumor cells. The present study, therefore, provided a molecular reference for the treatment of liver cancer. PMID: 25572801
48. Over-expression of Skp2 resulted in the increased cell growth and number of S phase cells in Skp2 transfected MCF-7 cells PMID: 26429528
49. Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in prostate cancer cells via regulation of Skp2, p53, p21Cip1, and p27Kip1. PMID: 25788262
50. Particularly for TNBC associated with Skp2/LRP6 overexpression. PMID: 25358452
顯示更多

收起更多
亞細胞定位：

Cytoplasm. Nucleus.
數(shù)據庫鏈接：

HGNC: 10901

OMIM: 601436

KEGG: hsa:6502

STRING: 9606.ENSP00000274255

UniGene: Hs.23348

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human